[1] Haugen BR, Alexander EK, Bible KC, et al.  2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[2] Rahmoun MN, Bendahmane I.  Anti-thyroglobulin antibodies in differentiated thyroid carcinoma patients: study of the clinical and biological parameters[J]. Ann Endocrinol (Paris), 2014, 75(1): 15-18.   doi: 10.1016/j.ando.2014.01.001
[3] Durante C, Tognini S, Montesano T, et al.  Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies[J]. Thyroid, 2014, 24(7): 1139-1145.   doi: 10.1089/thy.2013.0698
[4] 丛慧, 梁军, 李方, 等.  分化型甲状腺癌治疗后TgAb变化趋势及其影响因素[J]. 中国医学科学院学报, 2015, 37(1): 61-65.   doi: 10.3881/j.issn.1000-503X.2015.01.011
Cong H, Liang J, Li F, et al.  Changes in thyroglobulin antibodies after treatment of differentiated thyroid cancer and its influencing factors[J]. Acta Acad Med Sin, 2015, 37(1): 61-65.   doi: 10.3881/j.issn.1000-503X.2015.01.011
[5] 南楠, 鲜于志群, 赵明, 等.  甲状腺球蛋白抗体与分化型甲状腺癌131I治疗效果的关系研究[J]. 国际放射医学核医学杂志, 2021, 45(9): 545-551.   doi: 10.3760/cma.j.cn121381-202007044-00094
Nan N, Xianyu ZQ, Zhao M, et al.  Studies on the relationship between thyroglobulin antibody and the therapeutic effect of 131I in patients with differentiated thyroid carcinoma[J]. Int J Radiat Med Nucl Med, 2021, 45(9): 545-551.   doi: 10.3760/cma.j.cn121381-202007044-00094
[6] 张娜, 梁军.  甲状腺乳头状癌131I清甲后甲状腺球蛋白抗体变化趋势及其与疗效的关系[J]. 中华核医学与分子影像杂志, 2018, 38(3): 168-171.   doi: 10.3760/cma.j.issn.2095-2848.2018.03.005
Zhang N, Liang J.  Changes of thyroglobulin antibody after 131I ablation in patients with papillary thyroid carcinoma and its relationship with efficacy[J]. Chin J Nucl Med Mol Imaging, 2018, 38(3): 168-171.   doi: 10.3760/cma.j.issn.2095-2848.2018.03.005
[7] 孙丹阳, 孟召伟, 谭建, 等.  年龄及甲状腺球蛋白抗体阳性水平对分化型甲状腺癌预后的影响[J]. 中华内分泌代谢杂志, 2021, 37(12): 1068-1074.   doi: 10.3760/cma.j.cn311282-20210225-00121
Sun DY, Meng ZW, Tan J, et al.  The influence of age and thyroglobulin antibody positive level on the prognosis of differentiated thyroid cancer[J]. Chin J Endocrinol Metab, 2021, 37(12): 1068-1074.   doi: 10.3760/cma.j.cn311282-20210225-00121
[8] 中华医学会核医学分会.  131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
Nuclear Medicine Association of the Chinese Medical Association.  131I guidelines of the treatment of differentiated thyroid carcinoma (2014 edition)[J]. Chin J Nucl Med Mol Imaging, 2014, 34(4): 264-278.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
[9]

Liu QH, Yin MT, Li GX. Antithyroglobulin antibody variation during follow-up has a good prognostic value for preoperative antithyroglobulin antibody-positive differentiated thyroid cancer patients: a retrospective study in southwest China[J/OL]. Front Endocrinol (Lausanne), 2021, 12: 774275[2022-03-23]. https://www.frontiersin.org/articles/10.3389/fendo.2021.774275/full. DOI: 10.3389/fendo.2021.774275.
[10] 中国临床肿瘤学会指南工作委员会.  中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021[J]. 肿瘤预防与治疗, 2021, 34(12): 1164-1200.   doi: 10.3969/j.issn.1674-0904.2021.12.013
Guidelines Working Committee of Chinese Society of Clinical Oncology.  Guidelines of Chinese Society of Clinical Oncology (CSCO) differentiated thyroid cancer[J]. J Cancer Control Treat, 2021, 34(12): 1164-1200.   doi: 10.3969/j.issn.1674-0904.2021.12.013
[11] 中华医学会核医学分会.  131I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(4): 218-241.   doi: 10.3760/cma.j.cn321828-20201113-00412
Nuclear Medicine Association of the Chinese Medical Association.  Guidelines for radioiodine therapy of differentiated thyroid cancer (2021 edition)[J]. Chin J Nucl Med Mol Imaging, 2021, 41(4): 218-241.   doi: 10.3760/cma.j.cn321828-20201113-00412
[12] Spencer C, Fatemi S.  Thyroglobulin antibody (TgAb) methods-Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer[J]. Best Pract Res Clin Endocrinol Metab, 2013, 27(5): 701-712.   doi: 10.1016/j.beem.2013.07.003
[13] Chiovato L, Latrofa F, Braverman LE, et al.  Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens[J]. Ann Intern Med, 2003, 139(5 Pt 1): 346-351.   doi: 10.7326/0003-4819-139-5_part_1-200309020-00010
[14] Tsushima Y, Miyauchi A, Ito Y, et al.  Prognostic significance of changes in serum thyroglobulin antibody levels of pre- and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients[J]. Endocr J, 2013, 60(7): 871-876.   doi: 10.1507/endocrj.ej12-0410
[15] Jo K, Kim MH, Ha J, et al.  Prognostic value of preoperative anti-thyroglobulin antibody in differentiated thyroid cancer[J]. Clin Endocrinol (Oxf), 2017, 87(3): 292-299.   doi: 10.1111/cen.13367